Page 42 - Eceptor News Today

Researchers describe the Treg-cell-inducing activity of lipid extracts from the feces of specific-pathogen-free mice.

Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.

Researchers described a novel strategy for controlling severe acute respiratory syndrome coronavirus 2.

LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

Infections and other diseases can cause red blood cells to rupture, releasing the oxygen-binding molecule hemoglobin, which breaks down into heme.

Severe SARS-CoV-2 infection is associated with a 1.31 higher risk of being diagnosed with cancer following hospital discharge, particularly renal, hematological, colon, and lung cancers, suggesting a potential link between the infection and undiagnosed cancer.

MyJournals.org - Science - G protein‐coupled receptor modulation of striatal dopamine transmission: Implications for psychoactive drug effects (British Journal of Pharmacology)

Researchers evaluated immune responses to COVID-19 BNT162b2 mRNA vaccinations among Indigenous Australian First Nations (FN) individuals by comorbidity and ethnicity.